A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Clinical Trial Grant

Duke Scholars

Principal Investigator Richard Francis Riedel Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Inhibrx, Inc

Start Date

May 17, 2022

End Date

August 23, 2026

Administered By

Duke Cancer Institute

Awarded By

Inhibrx, Inc

Start Date

May 17, 2022

End Date

August 23, 2026